

I. Background

This grant request was jointly developed through a collaboration between Bayer Pharmaceuticals' Medical Education department and the Lilly Grant Office IME department. Should you decide to respond, you will be required to submit two separate applications: one to Bayer and one to Lilly. There may be some differences in information required by each company, as more specifically provided below.

Bayer and Lilly are committed to funding independent medical education initiatives that help to address important healthcare professional educational gaps and improve patient care. Bayer and Lilly do not support Independent Medical Education, or any medical activities, for the purpose of encouraging off-label use of their products.

II. General Information and Requirements

CGA Issue Date:	March 15, 2022
CGA Due Date:	March 15, 2022 – April 21, 2022
Initiation of Program Launch:	July – September 2022 (post-ASCO)
Therapeutic Area:	<ul style="list-style-type: none">• The biology of and rationale for targeting cancers driven by oncogenic drivers (such as <i>NTRK</i> gene fusions, <i>RET</i> and <i>ALK</i> genomic alterations, etc.)• How to identify patients with cancer who should be tested for gene fusions with established and emerging biomarker assays• Guidelines and recommendations for biomarker testing in a range of cancers and the impact of gene fusion identification in the treatment of the cancer• Data supporting the use of biomarker-driven treatment approaches in a range of cancers harboring the select oncogenic driver
Type of Initiative:	Online accredited educational program after a Congress/Conference (for example, ASCO or similar) with online and/or print educational activities
Activity Format Examples:	Online program with enduring materials/learner-centered, active-learning/Evidence-based learning & improvement programs which integrate the latest data available preferred
Primary Target Audience:	Medical and Clinical Oncologists; Pathologists; Molecular Pathologists; Nurses
Geographic Scope:	Global (including, US, Europe, and Asia Pacific); <i>HCPs located in the United Kingdom are not included in the targeted reach.</i>
Expected Monetary Range:	Range \$ 100,000 – 300,000 joint support between Bayer and Lilly
How to Submit:	<p>Please submit the same proposal to both the Bayer and Lilly Grant offices</p> <p>For Bayer:</p> <ol style="list-style-type: none">1. Review Bayer Pharmaceuticals Grant Guidelines: https://www.grants-contributions.bayer.com/home/medical-educational-grants2. Review additional CGA requirements outlined within this document3. Submit via Bayer Pharmaceuticals' online request form:

	https://www.grants-contributions.bayer.com/home/medical-educational-grants NOTE: Please reference ‘ Tumor-agnostic Testing CGA ’ in the title. For Lilly: When submitting your proposal, you must include “RFP: [title of program]” in your grant submission. All responses to this RFP are to be submitted online through the Lilly Grant Office grant application system at https://portal.lillygrantoffice.com
Questions:	Questions may be submitted to both Bayer Pharmaceuticals Medical Education at medicaleducation@bayer.com AND the Lilly Grant Office at lillygrantoffice@lilly.com .
Notification Process:	Upon evaluation and assessment by Bayer and Lilly, the requestor will be notified of an approval via e-mail to the address entered on the Grant Request. Decisions for submissions not selected will be sent via email from Bayer and posted on the Lilly Grant Portal.

III. Proposal Requirements

a. Formal letter of request/executive summary, including:

- i. Program title
- ii. Brief Program Outline/description
- iii. Program development start date
- iv. Target release date of program (if applicable)
- v. Rationale and approach to program placement (if applicable)
- vi. Anticipated attendance and breakdown by specialty (if applicable)
- vii. Amount requested
- viii. CME credits offered
- ix. Support structure/rationale

b. Needs Assessment

c. **Learning Objectives and Educational Gaps:** specific, measurable, performance based.

d. **Target Audience and Audience Generation:** describe the target audience(s) and provide a rationale for how and why this target audience is important to closing the identified healthcare gap. Additionally, describe methods of reaching the target audience(s) including description and rationale for recruitment strategies.

e. **Educational Method and Design:** considers appropriate target audience and learning preferences.

f. **Venue (if applicable):** describe target venue (i.e., distribution amongst academic institutions, large community hospitals and networks, restaurants, and others).

g. **Meeting Placement Strategy and Institution Vetting Process (if applicable)**

h. **Delivery Format:** describe rationale of delivery format

i. **Potential Faculty**

j. **Faculty Recruitment and Training Strategy**

k. **Program Development Timeline**

l. **Program Agenda**

m. **Program Budget:** detailed budget with rationale including breakdown of costs with clear calculations.

n. **Educational Outcomes:** provide a description of the approach to evaluate the reach and quality of program delivery (minimum outcomes: Moore's levels 1-4).

o. **Communication/Activity Update Plan (optional)**

IV. Compliance: grant application must be compliant with ACCME guidelines, free of commercial bias/influence, non-promotional, and fair balanced.

V. Terms and Conditions

a. This CGA does not commit Bayer Pharmaceuticals or Eli Lilly and Company to award a grant or to pay any costs incurred in the preparation of this request.

b. Bayer Pharmaceuticals and Eli Lilly and Company reserve the right to accept or reject any or all applications received as a result of this request or to cancel in part or in its entirety this CGA at any time without prior notification or permission.

c. The grant application must be submitted via:

1. Bayer Pharmaceuticals' online request form: <https://www.grants-contributions.bayer.com/home/medical-educational-grants> and
2. Lilly Grant Office grant application system at <https://portal.lillygrantoffice.com>

d. All communications about the CGA must come to both Bayer Pharmaceuticals Medical Education at medicaleducation@bayer.com **AND** the Lilly Grant Office at lillygrantoffice@lilly.com.